Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab

• Main Authors: Andrey L. Bakulev (Author), Larisa S. Kruglova (Author)
• Formato: Libro
• Publicado: State Scientific Center of Dermatovenereology and Cosmetology, 2022-09-01T00:00:00Z.
• Subjects: article
• Acceso en liña: Connect to this object online.

A review of the literature on the use of the genetically engineered biological drug Skyrizi (INN: risankizumab) for the treatment of psoriasis in patients is presented. The problem of high dissatisfaction of patients with the available means (methods) of therapy for this dermatosis is discussed. Inh...